Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
First Valley Medical Group
Lancaster, California, United States
Torrance Clinical Research Institute, Inc.
Lomita, California, United States
Ark Clinical Research
Long Beach, California, United States
Pacific Clinical Studies
Los Alamitos, California, United States
Wetlin Research Associates, Inc.
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Encore Medical Research LLC
Hollywood, Florida, United States
Bioclinical Research Alliance
Miami, Florida, United States
South Broward Research LLC
Miramar, Florida, United States
West Orange Endocrinology
Ocoee, Florida, United States
Start Date
April 17, 2026
Primary Completion Date
September 3, 2027
Completion Date
September 3, 2027
Last Updated
March 11, 2026
270
ESTIMATED participants
NNC0662-0419
DRUG
Semaglutide
DRUG
Placebo
DRUG
Lead Sponsor
Novo Nordisk A/S
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062